deltatrials
Completed PHASE1 INTERVENTIONAL 24-arm NCT02009449

A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors (IVY)

A Phase 1, Open-Label Dose Escalation First-in-Human Study to Evaluate the Tolerability, Safety, Maximum Tolerated Dose, Preliminary Clinical Activity and Pharmacokinetics of AM0010 in Patients With Advanced Solid Tumors

Sponsor: ARMO BioSciences

Conditions Breast Cancer Colorectal Carcinoma Melanoma Non-small Cell Lung Carcinoma Ovarian Cancer Pancreatic Carcinoma Prostate Cancer Renal Cell Carcinoma Solid Tumors
Interventions Capecitabine FOLFOX (Oxaliplatin/Leucovorin/5-Fluorouracil) Gemcitabine/carboplatin Paclitaxel Paclitaxel or Docetaxel and Carboplatin or Cisplatin Pazopanib Pegilodecakin Pembrolizumab gemcitabine/nab-paclitaxel nivolumab
Updated 14 times since 2017 Last updated: Nov 13, 2024 Started: Nov 15, 2013 Primary completion: Feb 19, 2019 Completion: Jul 22, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Breast Cancer and Colorectal Carcinoma, this trial is completed. The trial is conducted by ARMO BioSciences and has accumulated 14 data snapshots since 2013. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshot~Jun 2018 – ~May 2019 · 11 months · monthly snapshot~May 2019 – ~Apr 2020 · 11 months · monthly snapshot~Apr 2020 – ~Jan 2021 · 9 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Jun 2021 · 4 months · monthly snapshot~Jun 2021 – ~Oct 2021 · 4 months · monthly snapshot~Oct 2021 – ~Dec 2022 · 14 months · monthly snapshot~Dec 2022 – ~Feb 2024 · 14 months · monthly snapshot~Feb 2024 – ~Jul 2024 · 5 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Dec 2024 · 3 months · monthly snapshot~Dec 2024 – present · 18 months · monthly snapshot

Change History

14 versions recorded

  1. Dec 2024 — Present [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

  2. Sep 2024 — Dec 2024 [monthly]

    Active Not Recruiting PHASE1

  3. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE1

  4. Feb 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE1

  5. Dec 2022 — Feb 2024 [monthly]

    Active Not Recruiting PHASE1

▶ Show 9 earlier versions

  1. Oct 2021 — Dec 2022 [monthly]

    Active Not Recruiting PHASE1

  2. Jun 2021 — Oct 2021 [monthly]

    Active Not Recruiting PHASE1

  3. Feb 2021 — Jun 2021 [monthly]

    Active Not Recruiting PHASE1

  4. Jan 2021 — Feb 2021 [monthly]

    Active Not Recruiting PHASE1

  5. Apr 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1

  6. May 2019 — Apr 2020 [monthly]

    Active Not Recruiting PHASE1

  7. Jun 2018 — May 2019 [monthly]

    Active Not Recruiting PHASE1

  8. Feb 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  9. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1

    First recorded

Nov 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • ARMO BioSciences
  • Eli Lilly and Company
Data source: Eli Lilly and Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations